STOCKHOLM - Continuous ruxolitinib therapy extends survival over that seen with best available therapy (BAT) in patients with myelofibrosis and also provides durable reductions in splenomegaly, according to results released at the 18th Congress of the European Hematology Association (EHA). The data, from a three-year follow-up of the phase 3 Myelofibrosis Study with Oral JAK Inhibitor Treatment II (COMFORT-II) study, also show that the agent continues to be well tolerated with prolonged treatment...
via Health News from Medical News Today Read More Here..
No comments:
Post a Comment